S&P 500
7,654.04
-103.13
-1.33%
Dow
52,673.20
-182.89
-0.35%
Nasdaq
26,089.03
-613.83
-2.30%
NYSE Composite
24,143.18
-109.94
-0.45%
Russell 2000
2,769.63
-11.39
-0.41%
VIX
19.12
+2.44
+14.63%
BHVN · Biohaven Ltd.
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
$14.90
+3.15
(+26.85%)
● Market open
DAY'S RANGE
$14.90
$14.91
$16.52
52-WEEK RANGE
$14.90
$7.48
$18.57
What's happening
- BHVN is up 26.85% today, trading at $14.90. — Live quote
- Volume today (288,037) is well below its 3-month average of 2,850,980. (Finnhub fundamentals)
- Reports earnings on 2026-11-17, 26 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.91 actual vs. $-0.75 estimated (-21.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 10
Hold 5
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (23 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BHVN
+4.61%
vs S&P 500
-8.17%
1-YEAR RETURN
BHVN
-32.67%
vs S&P 500
-47.23%
6-MONTH RETURN
BHVN
+17.98%
3-MONTH RETURN
BHVN
-23.86%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.91
Est. $-0.75
MISS -21.7%
2026-04-26 (Q1 2026)
$-0.88
Est. $-0.84
MISS -4.2%
2026-01-26 (Q4 2025)
$-1.21
Est. $-1.32
BEAT +8.0%
2025-10-26 (Q3 2025)
$-1.64
Est. $-1.93
BEAT +15.0%
Valuation Measures & Ratios
Enterprise Value4$1.80B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book7183.30
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-639.95%
Return on Assets (ROA9)-138.27%
Avg Volume (3M)2,850,980
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.25B | $1.25B | $1.59B | $1.44B | $2.46B |
| P/E | -3.52 | -1.73 | -2.11 | -1.60 | -2.79 |
| Price/Book | 184.08 | 9.68 | -92.57 | 10.71 | 9.46 |
| EV/EBITDA | -3.21 | -1.36 | -1.82 | — | — |
| ROE | -5231.82% | -558.92% | 4391.44% | -668.64% | -339.60% |
| ROA | -172.48% | -155.19% | -184.19% | -163.49% | -192.02% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,053,695
Change from Prior Settlement-6.82%
% of Float—
Days to Cover (Short Ratio)6.43
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-22; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -32.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BHVN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$124.9M | -$130.4M | -$169.4M | -$211.7M | -$221.6M | -$178.2M | -$333.8M | -$183.2M |
| Net income | -$137.3M | -$130.5M | -$173.4M | -$198.1M | -$221.7M | -$160.3M | -$319.8M | -$179.5M |
| EPS (diluted) | $-0.91 | $-0.88 | $-1.64 | $-1.94 | $-2.17 | $-1.70 | $-3.64 | $-2.20 |
| EPS (basic) | $-0.91 | $-0.88 | $-1.64 | $-1.94 | $-2.17 | $-1.70 | $-3.64 | $-2.20 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $370.7M | $466.4M | $451.4M | $409.1M | $550.4M | $458.9M | $615.1M | $510.5M |
| Total liabilities | $358.5M | $336.9M | $399.4M | $426.3M | $415.8M | $199.5M | $191.7M | $194.5M |
| Stockholders' equity | $12.2M | $129.5M | $52.1M | -$17.2M | $134.6M | $259.5M | $423.4M | $316.0M |
| Total current assets | $296.6M | $385.6M | $368.3M | $323.6M | $474.8M | $382.8M | $538.5M | $440.5M |
| Total current liabilities | $62.7M | $52.1M | $115.9M | $113.0M | $124.3M | $164.0M | $154.2M | $152.3M |
| Cash & equivalents | $238.0M | $273.1M | $230.0M | $184.8M | $165.8M | $98.4M | $99.1M | $84.4M |
| Marketable securities (current) | $29.8M | $74.7M | $89.2M | $75.4M | $239.2M | $224.3M | $386.9M | $294.4M |
| Other current assets | $1.7M | $3.2M | $2.2M | $8.4M | $8.4M | $3.6M | $3.1M | $1.2M |
| Property, plant & equipment | $15.1M | $15.3M | $16.0M | $17.5M | $18.6M | $17.8M | $17.3M | $18.3M |
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M |
| Intangible assets | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M |
| Other non-current assets | $39.3M | $45.7M | $47.4M | $48.2M | $37.2M | $38.6M | $39.5M | $32.0M |
| Accounts payable | $12.1M | $10.4M | $11.6M | $17.5M | $19.6M | $19.1M | $18.0M | $19.7M |
| Accrued liabilities | $50.5M | $41.7M | $104.3M | $73.5M | $78.7M | $56.6M | $51.5M | $63.5M |
| Other non-current liabilities | $3.5M | $4.6M | $4.6M | $4.6M | $4.6M | $4.6M | $4.7M | $4.6M |
| Common stock & paid-in capital | $2.14B | $2.13B | $1.93B | $1.74B | $1.74B | $1.69B | $1.66B | $1.38B |
| Retained earnings | -$2.35B | -$2.22B | -$2.08B | -$1.94B | -$1.77B | -$1.57B | -$1.35B | -$1.16B |
| Accumulated other comprehensive income (loss) | $5.4M | $8.3M | $8.3M | $36.0K | -$3.0K | $73.0K | $79.0K | $140.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$85.1M | -$149.9M | -$130.7M | -$145.7M | -$167.9M | -$165.1M | -$170.7M | -$141.3M |
| Investing cash flow | $44.8M | $15.2M | -$13.7M | $165.0M | -$15.5M | $164.9M | -$87.7M | -$93.4M |
| Financing cash flow | $3.8M | $179.0M | $188.8M | $122.0K | $249.8M | $369.0K | $272.9M | $80.4M |
| Free cash flow | -$85.6M | -$149.9M | -$130.7M | -$145.7M | -$168.2M | -$165.6M | -$170.8M | -$141.9M |
| Capital expenditures | $454.0K | $0 | $8.0K | $13.0K | $233.0K | $461.0K | $49.0K | $611.0K |
| Depreciation & amortization | $2.3M | $2.4M | $2.6M | $3.1M | $2.0M | $2.2M | $2.5M | $2.0M |
| Share-based compensation | $19.2M | $28.3M | $59.3M | $21.5M | $20.8M | $53.1M | $37.1M | $12.2M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts payable | $1.7M | -$1.2M | -$5.8M | -$2.1M | $1.5M | $91.0K | -$1.7M | $2.5M |
| Purchases of investments | $29.7M | $19.8M | $88.7M | $0 | $133.5M | $44.7M | $279.6M | $222.8M |
| Sales/maturities of investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other investing activities | $0 | — | $0 | $20.0K | $1.8M | — | $391.0K | $0 |
| Other financing activities | $0 | $0 | -$194.0K | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$745.4M | -$885.1M | -$436.1M | -$567.9M | -$218.9M |
| Net income | -$738.8M | -$846.4M | -$408.2M | -$570.3M | -$213.8M |
| EPS (diluted) | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 |
| EPS (basic) | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $451.4M | $615.1M | $513.2M | $661.8M | $142.1M |
| Total liabilities | $399.4M | $191.7M | $85.2M | $123.0M | $47.4M |
| Stockholders' equity | $52.1M | $423.4M | $428.0M | $538.8M | $34.7M |
| Total current assets | $368.3M | $538.5M | $442.4M | $587.0M | $94.8M |
| Total current liabilities | $115.9M | $154.2M | $55.4M | $90.0M | $41.9M |
| Cash & equivalents | $230.0M | $99.1M | $248.4M | $204.9M | $76.1M |
| Marketable securities (current) | $89.2M | $386.9M | $133.4M | $260.5M | $0 |
| Other current assets | $2.2M | $3.1M | $12.1M | $19.3M | $2.1M |
| Property, plant & equipment | $16.0M | $17.3M | $17.2M | $17.5M | $13.0M |
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M |
| Intangible assets | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M |
| Other non-current assets | $47.4M | $39.5M | $33.8M | $37.5M | $14.4M |
| Accounts payable | $11.6M | $18.0M | $15.6M | $10.7M | $4.8M |
| Accrued liabilities | $104.3M | $51.5M | $39.8M | $44.1M | $37.2M |
| Other non-current liabilities | $4.6M | $4.7M | $2.2M | $2.4M | $2.6M |
| Common stock & paid-in capital | $1.93B | $1.66B | $887.5M | $615.7M | $0 |
| Retained earnings | -$2.08B | -$1.35B | -$499.3M | -$91.1M | $0 |
| Accumulated other comprehensive income (loss) | $8.3M | $79.0K | -$65.0K | $284.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$609.4M | -$582.5M | -$331.7M | -$297.7M | -$145.8M |
| Investing cash flow | $300.6M | -$245.0M | $129.8M | -$304.8M | $944.0K |
| Financing cash flow | $439.1M | $677.8M | $211.9M | $767.6M | $138.4M |
| Free cash flow | -$610.2M | -$586.5M | -$334.8M | -$303.8M | -$146.8M |
| Capital expenditures | $715.0K | $4.0M | $3.0M | $6.1M | $938.0K |
| Depreciation & amortization | $9.9M | $7.9M | $6.9M | $1.4M | $1.4M |
| Share-based compensation | $112.4M | $72.0M | $28.8M | $193.6M | $65.6M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts payable | -$6.4M | $710.0K | $4.9M | $5.9M | $1.0M |
| Purchases of investments | $266.9M | $745.7M | $194.1M | $259.7M | $0 |
| Sales/maturities of investments | $0 | $0 | $4.9M | $0 | $0 |
| Other investing activities | $1.8M | $0 | $0 | — | — |
| Other financing activities | -$194.0K | $2.3M | $0 | $0 | $395.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BHVN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers74.5%
Shares Outstanding150,636,620
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,210,585 | $196.6M | 8.77% | +17.7% | 2026-08-07 |
| MONTANOVA CAPITAL, LLC | 10,286,937 | $153.1M | 6.83% | +0.0% | 2026-08-14 |
| Stifel Financial Corp | 9,941,165 | $147.9M | 6.60% | +0.0% | 2026-08-12 |
| Jupiter Topco LLC | 8,584,675 | $127.9M | 5.70% | +0.0% | 2026-08-14 |
| Woodline Partners LP | 7,660,280 | $114.0M | 5.09% | +2450.1% | 2026-08-14 |
| State Street Corp | 6,947,034 | $103.4M | 4.61% | +5.0% | 2026-08-07 |
| INFINITUM ASSET MANAGEMENT, LLC | 6,250,000 | $93.0M | 4.15% | +0.0% | 2026-08-14 |
| D. E. Shaw & Co., Inc. | 4,190,195 | $62.4M | 2.78% | +47.2% | 2026-08-14 |
| AQR CAPITAL MANAGEMENT LLC | 4,150,616 | $61.8M | 2.76% | +110.1% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,323,190 | $49.5M | 2.21% | +20.1% | 2026-08-12 |
| FMR LLC | 2,964,630 | $44.1M | 1.97% | +25.7% | 2026-08-13 |
| Royalty Pharma Sub-Manager, LLC | 2,936,507 | $43.7M | 1.95% | +0.0% | 2026-08-14 |
| Cormorant Asset Management, LP | 2,610,000 | $38.8M | 1.73% | +48.3% | 2026-08-14 |
| Goldman Sachs Group Inc | 2,583,046 | $38.4M | 1.71% | +2.8% | 2026-08-14 |
| UBS Group AG | 2,518,827 | $37.5M | 1.67% | +76.6% | 2026-08-13 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,488,941 | $37.0M | 1.65% | +9.2% | 2026-06-30 |
| Knoll Capital Management, LLC | 2,328,602 | $15 | 1.55% | +0.0% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 1,879,734 | $28.0M | 1.25% | -23.1% | 2026-08-13 |
| TCG Crossover Management, LLC | 1,779,952 | $26.5M | 1.18% | -61.6% | 2026-08-12 |
| Nuveen, LLC | 1,744,334 | $26.0M | 1.16% | +133.9% | 2026-08-11 |
| Rubric Capital Management LP | 1,721,493 | $25.6M | 1.14% | +0.0% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,619,676 | $24.1M | 1.08% | -6.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,488,809 | $22.2M | 0.99% | +17.2% | 2026-06-30 |
| Bank Of America Corp /De/ | 1,477,838 | $22.0M | 0.98% | +94.6% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,456,851 | $21.7K | 0.97% | -34.3% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-13 to 2026-03-17
Recent transactions
- Most recent: Mehta Kishan (Director) — Gift of 17,342 shares on 2026-03-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Mehta Kishan | Director | Gift | 2026-03-17 | 17,342 |
| Gentile Kimberly | SVP, Clinical Operations | Option exercise | 2026-01-05 | 3,750 |
| Buten Matthew | Chief Financial Officer | Option exercise | 2026-01-05 | 4,250 |
| Coric Vlad | Chief Executive Officer | Option exercise | 2026-01-05 | 14,250 |
| Car Bruce | Chief Scientific Officer | Option exercise | 2026-01-05 | 4,750 |
| Clark George C. | VP, Chief Accounting Officer | Option exercise | 2026-01-05 | 2,500 |
| Bailey Gregory | Director | Open market purchase | 2025-11-13 | 400,000 |
| CHILDS JOHN W | Director | Open market purchase | 2025-11-13 | 3,333,333 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-17 | Mehta Kishan | Director | Gift | 17,342 | $0.00 |
| 2026-03-17 | Mehta Kishan | Director | Gift | 17,342 | $0.00 |
| 2026-01-05 | Gentile Kimberly | SVP, Clinical Operations | Option exercise | 3,750 | $0.00 |
| 2026-01-05 | Gentile Kimberly | SVP, Clinical Operations | Tax withholding | 1,956 | $9.93 |
| 2026-01-05 | Buten Matthew | Chief Financial Officer | Option exercise | 4,250 | $0.00 |
| 2026-01-05 | Buten Matthew | Chief Financial Officer | Tax withholding | 2,594 | $9.93 |
| 2026-01-05 | Coric Vlad | Chief Executive Officer | Option exercise | 14,250 | $0.00 |
| 2026-01-05 | Coric Vlad | Chief Executive Officer | Tax withholding | 7,430 | $9.93 |
| 2026-01-05 | Car Bruce | Chief Scientific Officer | Option exercise | 4,750 | $0.00 |
| 2026-01-05 | Car Bruce | Chief Scientific Officer | Tax withholding | 2,381 | $9.93 |
| 2026-01-05 | Clark George C. | VP, Chief Accounting Officer | Option exercise | 2,500 | $0.00 |
| 2026-01-05 | Clark George C. | VP, Chief Accounting Officer | Tax withholding | 1,117 | $9.93 |
| 2025-11-17 | Clark George C. | VP, Chief Accounting Officer | Open market purchase | 17,000 | $8.52 |
| 2025-11-13 | Bailey Gregory | Director | Open market purchase | 400,000 | $7.50 |
| 2025-11-13 | CHILDS JOHN W | Director | Open market purchase | 3,333,333 | $7.50 |
| 2025-11-13 | Coric Vlad | Chief Executive Officer | Open market purchase | 333,333 | $7.50 |
| 2025-11-13 | Coric Vlad | Chief Executive Officer | Open market purchase | 333,333 | $7.50 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 11:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-22 | 8-K | 2026-10-22 | View on SEC.gov → |
| 2026-10-15 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-10 | 8-K | 2026-09-04 | View on SEC.gov → |
| 2026-08-26 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-09 | 8-K | 2026-07-09 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-26 | View on SEC.gov → |
| 2026-05-05 | 8-K | 2026-05-04 | View on SEC.gov → |
| 2026-05-04 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about BHVN (Biohaven Ltd.). Links open the publisher — we don’t host full articles.
-
Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting
Yahoo Finance · 2026-10-22 -
Why Is Biohaven Stock Soaring Today? - Biohaven (NYSE:BHVN)
Benzinga · 2026-10-22 -
Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug Vyglxia
International Business Times Australia · 2026-10-22 -
Baird raises Biohaven Pharma stock price target on NDA acceptance
Investing.com · 2026-10-22 -
BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia
Yahoo Finance · 2026-10-22 -
Biohaven surges as FDA accepts resubmission for Vyglxia for spinocerebellar ataxia
Seeking Alpha · 2026-10-22 -
Why Biohaven's 36% Surge Might Just Be The Beginning
Investor's Business Daily · 2026-10-22 -
Biohaven (BHVN) Jumps As Ono Deal Delivers Cash And Validation
StocksToTrade · 2026-10-22
No headlines in this category right now — try “All”.